Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab

Main Article Content

Kim A Papp
Andrew Blauvelt
Mary Flack
Yihua Gu
Elizabeth HZ Thompson


psoriasis, risankizumab, ustekinumab, biologic therapy


Abstract Not Available


Disclosures: Study supported by AbbVie.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>